Unravel Biosciences is a therapeutics company spun out from the Wyss Institute at Harvard University that seamlessly bridges target discovery with clinical efficacy to advance drugs for complex neurological diseases where traditional target-driven drug programs have often failed. Unravel leverages its proprietary BioNAV™ platform combining AI drug discovery, patient stratification, preclinical screening, and rapid clinical trials to discover effective treatments for complex diseases impacting the whole body. Central to Unravel’s unique capabilities is its suite of automated behavioral and cognitive screening instruments coupled with Xenopus tadpole disease models that allows for high-throughput screening in vivo at the earliest steps of a therapeutics program, uncovering effective drugs and novel targets in parallel. When coupled with Unravel’s proprietary transcriptomic network model of human health, the iterative predict-evaluate process results in high-value, actionable targets as the output, inverting the traditional drug discovery to accelerate drug and target discovery with lower development risk. Unravel’s target-agnostic approach has resulted in the identification of RVL001, a promising proprietary formulation targeting Rett Syndrome that will enter the clinic in late 2022, and discovery of RVL002, a new small molecule with potential applications in CNS and metabolic diseases.
Meet Our Team
The team of scientists behind Unravel Bio is dedicated to bringing effective drugs to patients based on technology developed at the Wyss Institute for Biologically Inspired Engineering at Harvard University. Their deep experience cutting across disciplines, including computational drug discovery, innovative animal models, automated drug screens, and entrepreneurship, is the keystone to building a new paradigm for accelerating drug development at lower cost and with lower risk.